TBAJ-876

Overview

TBAJ-876 is an orally active diarylquinoline anti- Mycobacterium agent. TBAJ-876 regulates energy metabolism by targeting the c and ε subunits of Mycobacterium tuberculosis F-ATP synthase, exerts bactericidal activity against replicating Mycobacterium tuberculosis , and retains activity against strains carrying the Rv0678 mutation. TBAJ-876 undergoes N-demethylation in vivo to form its major active metabolite TBAJ-876-M3, which has lower lipophilicity and hERG potassium channel binding affinity. TBAJ-876 is well tolerated in BALB/c mice and significantly reduces the colony-forming units of Mycobacterium tuberculosis in the lungs. In addition, TBAJ-876 exhibits inhibitory activity against Mycobacterium abscessus , reduces bacterial loads in the lungs and spleens of infected mice, and shows no antagonistic effect when used in combination with common antibiotics . TBAJ-876 can be used in studies related to tuberculosis and Mycobacterium abscessus pulmonary diseases.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Bacterial Infection | Products > Disease Areas > Mycobacterium Tuberculosis Infection | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > Bacterial

Product Information

• Catalog No.: HY-128866
• CAS No.: 2332841-25-3
• Molecular Formula: C31H37BrN4O7
• Molecular Weight: 657.55
• Purity: 99.98%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Source

Original product source